|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Supplementary Table S3.** Summary of best overall response, prior immunotherapy, and duration of responses by tumor type (RECIST) | | | | | |
| **Cancer Type** | **HCC**  **n = 19** | **MEL**  **n = 15** | **RCC**  **n = 9** | **HNSCC**  **n = 9** | **Total**  **N = 52** |
| BOR, *n* (%) |  |  |  |  |  |
| CR | 0 | 0 | 0 | 0 | 0 |
| PR | 1 (5.3) | 2 (13.3) | 0 | 0 | 3 (5.8) |
| SD | 10 (52.6) | 7 (46.7) | 5 (55.6) | 4 (44.4) | 26 (51.9) |
| PD | 7 (36.8) | 5 (33.3) | 4 (44.4) | 3 (33.3) | 19 (36.5) |
| Indeterminate (%) | 1 (5.3) | 0 | 0 | 0 | 1 (1.9) |
| NE | 0 | 1 (6.7) | 0 | 2 (22.2) | 3 (5.8) |
| Patients with prior immunotherapy, *n* | 4 | 15 | 1 | 2 | 22 |
| Mean DOR, weeks | 93.1 | 23.1 | – | – | 46.4 |
| Mean DOSD, weeks | 14.4 | 11.3 | 15.8 | 20.2 | 14.7 |
| Median time to first PD, weeks | 11.6 | 9.7 | 11.6 | 15.9 | 11.6 |

Time to first PD: time from start of treatment until date of first PD or the last non-PD assessment date prior to cut-off date. Prior immunotherapy: anti-PD-1, anti-PD-L1, anti-CTLA-4 therapy, or IFNα.

BOR, best overall response; CR, complete response; DOR, duration of response; DOSD, duration of stable disease; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; IFNα, interferon alpha; MEL, malignant melanoma; NE, not evaluable; PD, progressive disease; PR, partial response; RCC, renal cell carcinoma; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease